Speciality: Hematology
Description:
A warm welcome to all the medical professionals to this session on "Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective." This session synthesizes the key takeaways from our discussion on ferric maltol, highlighting its transformative potential in the management of iron deficiency anemia (IDA). The overarching new perspective is a shift away from the traditional, one-size-fits-all approach to oral iron supplementation, toward a more nuanced and patient-focused strategy.
The primary limitation of standard oral iron salts is their high incidence of gastrointestinal (GI) side effects, which leads to poor patient adherence and treatment failure. Ferric maltol provides a new perspective by addressing this issue directly. Its unique chemical structure, a stable complex of ferric iron (Fe³⁺) and maltol, minimizes the release of free iron in the gut, thereby reducing GI irritation and inflammation. This improved tolerability is not just a secondary benefit; it is a core feature that can lead to better treatment compliance and, ultimately, more effective iron repletion.
In conclusion, the new perspective is that ferric maltol is not simply another oral iron option, but a clinically meaningful alternative that overcomes the historical drawbacks of traditional oral iron. Its proven efficacy and favorable tolerability profile, particularly in challenging patient populations like those with inflammatory bowel disease or chronic kidney disease, position it as a valuable tool in the modern management of IDA. This allows clinicians to choose a therapy that is both effective and well-tolerated from the outset, leading to a better quality of life for patients.
See More Webinars @ Hidoc Webinars
1.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
2.
According to JAMA, women who have false-positive mammogram results are at a higher risk of developing breast cancer over time.
3.
COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment
4.
It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.
5.
Both men and women who receive the HPV vaccine have a lower risk of developing multiple cancer types.
1.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
2.
Case Study: Genomic Medicine in Precision Oncology
3.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
4.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
5.
Advancing Medical Oncology: Education, Certification, Clinical Trials, and Evolving Treatment Pathways
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation